Kalaris Therapeutics (KLRS)

• Market cap: $117M
• 1 day: -3.91%
• 5 days: 0.61%
• 1 month: -22.27%
• 3 months: -54.32%
• 6 months: -23.72%
• Year to date: -40.72%
• 1 year: 73.85%
• 5 years: -99.01%
• 10 years: -99.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Employees: 20